PEGASEMP™
We have developed a proprietary targeted pegylated platform for the delivery of small molecular weight drugs. The proof-of-concept was originally validated with the encapsulation of doxorubicin in the aqueous core of the system. An initial application testing of the platform’s targeting ability translated to therapeutic efficacy and safety in an animal model of breast cancer.
The platform accumulated specifically in the tumor and completely suppressed tumor invasiveness into the surrounding healthy tissues. Specificity of action was confirmed with breast tumor cells harvested from patients submitted to mastectomy, regardless expression of HER2, progesterone or estrogen receptors. The novelty of PEGASEMP™ relies on its dual ability to target tumor cells and endothelial cells from angiogenic blood vessels.
| Target discovery |
Delivery platform development |
Pre-clinical | Clinical Phase I and II |
Clinical Phase III |
|
|---|---|---|---|---|---|
| Breast |  |
||||
| Mesothelioma | |
||||
| Lung |
 |
||||
| Prostate | |
||||
| Melanoma | |
||||
| Leukemia | |
||||
